custom tirzepatide Compounded Client-submitted results 🤍 She's 35.

SURMOUNT-J 267 BMI 33.559%51 72 10mg -16.1% 15mg -21.1% 5% 10mg9015mg96 4%10mg 4%15mg 0% Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Tirzepatide demonstrates strong efficacy and a manageable safety profile in clinical trials, though individual responses vary

Mild increases in pancreatic enzyme levels were observed in both groups, with higher elevations in the dulaglutide group

Tirzepatide reaches maximum blood concentration between 8 and 10 days after injection, though individual response timing varies based on body composition, metabolism, and genetic factors

Mixing alcohol with GLP-1 medications like semaglutide requires careful consideration